Can-Fite BioPharma (NYSE MKT:CANF; TASE:CFBI) has reported new findings for its drug candidate, CF602, showing statistically significant full recovery from erectile dysfunction after one single dose treatment in a preclinical diabetic model.
Can-Fite plans to file an IND application with the FDA for CF602 in the fourth quarter this year and plans to initiate a Phase 1 trial following IND approval.
Statistically significant full recovery from erectile dysfunction took place in rats treated with a 500 µ/kg dose.
There is a significant segment of the erectile dysfunction market that is not addressed by PDE5 inhibitors, the class of drugs that are widely used in the market today.
Due to CF602’s novel mechanism of action, it may provide benefits for patients who do not respond to PDE5 inhibitors, or cannot take PDE5 inhibitors due to contraindications.
“These latest findings for CF602 are very encouraging and they add to the growing body of data that forms the basis of our planned IND submission to the FDA,” Can-Fite CEO, Dr. Pnina Fishman, said in a statement.
